Series B · Biotech · Zurich, Switzerland · Founded 2017 · 20–50 employees
Hemotune AG is a 2017 ETH Zurich spin-off developing a revolutionary blood purification technology using magnetic nanoparticles to target sepsis and restore immune balance more precisely than dialysis. It has raised over CHF 18M including a CHF 14M Series B2 round to fund clinical trials starting in 2024. The HemoSystem aims to improve patient outcomes in critical illnesses by removing disease-causing substances efficiently.
No open roles listed right now.